Nanotherapeutics for the treatment of hepatocellular carcinoma / edited by Biswajit Mukherjee.

Format:

Book

Author/Creator:

Mukherjee, Biswajit, Author.

Contributor:

Mukherjee, Biswajit, editor.

Language:

English

Subjects (All):

Liver--Cancer--Treatment.

Liver.

Nanomedicine.

Physical Description:

1 online resource (557 pages)

Edition:

First edition.

Place of Publication:

Singapore : Bentham Science Publishers Pte. Ltd., [2022]

Summary:

Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics have shown considerable potential and there is tremendous impetus for rapid translation from the pre-clinical to the clinical domain to significantly prolong the survival in HCC. In Nanotherapeutics for the Treatment of Hepatocellular Carcinoma, authoritative experts of the field have explored the important aspects of nanotherapeutics against HCC. The book exhaustively, vividly and explicitly describes the molecular pathogenesis, diagnostic aspects and nanotherapy of HCC, while also highlighting the challenges of conventional therapy and the benefits of nanotherapeutics. Chapters of the book also cover recent investigations of nanotherapeutics against HCC, types of nanomedicines, recent patents, commercially available nanotherapeutics and a future perspective to give a comprehensive review of the topic to readers. In addition to these defining features, the book provides several references for further reading. The book is an ideal resource on HCC nanotherapeutics for medical and pharmacology postgraduate students, faculties, researchers, and biomedical scientists working on HCC and nanotherapy.

Contents:

Cover

Title

Copyright

End User License Agreement

Contents

Preface

List of Contributors

Hepatocellular Carcinoma: Diagnosis, Molecular Pathogenesis, Biomarkers, and Conventional Therapy

Biswajit Mukherjee*, 1, Manasadeepa Rajagopalan2, Samrat Chakraborty1, Prasanta Ghosh1, Manisheeta Ray1, Ramkrishna Sen1 and Iman Ehsan1

INTRODUCTION

CANCER AND ITS TYPES

Primary Liver Cancer

Hepatocellular Carcinoma (HCC)

Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)

Angiosarcoma and Hemangiosarcoma

Hepatoblastoma

Secondary Liver Cancer Surgical Resection in Advanced HCC

Anatomical Resection

Laparoscopic Resection of The Liver

Surgical Resection of Re-Occurring HCC

Liver Transplantation

Ablation

Palliative Treatment

Embolizing Therapies for HCC

Transarterial Chemoembolization (TACE)

Radiotherapy

Systemic Therapies of HCC

First-line Therapy

Second-line Therapy

Multi-Target Tyrosine Kinase Inhibitors

Immune Checkpoint Inhibitor

FUTURE PERSPECTIVES

CONCLUSIONS

CONSENT FOR PUBLICATION

CONFLICT OF INTEREST

ACKNOWLEDGEMENT

REFERENCES DETAIL DESCRIPTION OF HCC

Staging System in HCC

Risk Factors for HCC

Pathophysiology of HCC

Molecular and Cellular Features of the Tumor Microenvironment

Importance of Cancer Stem Cells in HCC

Inflammation and HCC

Oxidative Stress in HCC

Epithelial-Mesenchymal Transition (EMT)

Hypoxia and HCC

Impairment of Cell Cycle in HCC

Loss of Senescence Control

Apoptosis and HCC

Cellular Signalling Pathways in HCC

EGF/TGF-a pathway

Insulin Growth Factor (IGF) Pathway

HGF/c-Met Pathway

Signaling Pathways Involved in Neovascularization in HCC

MAPK Pathways PI3K/Akt/mTOR Pathway

Signaling Pathways Related to Cell Differentiation and Development

Wnt-ß Catenin Pathway

Hedgehog (Hh) Signaling

Notch Pathway

Hippo Pathway

Target Receptor(s) and Biomarker Proteins in HCC

Asialoglycoprotein Receptor

Glypican-3 (GPC3)

Transferrin Receptor (TfR)

Heat Shock Protein 70 (HSP70)

Tumor-Associated Glycoprotein-72 (TAG-72)

Golgi Protein73 (GP73)

Ki-67 Antigen

Somatostatin Receptor (SSTR)

Homodimeric Glycoprotein (AF-20)

Osteopontin (OPN)

Des-?-Carboxyprothrombin

a-Fetoprotein (AFP) Squamous Cell Carcinoma Antigen (SCCA)

Hepatocyte Paraffin 1 (HepPar1)

APO-J

DKK-1 (Dickkopf-p1)

Human Carbonyl Reductase 2 (HCR2)

Midkine

Nerve Growth Factor (NGF)

Vascular Endothelial Growth Factor (VEGF)

Transforming Growth Factor-ß (TGF-ß)

Epidermal Growth Factor (EGFR)

Hepatocyte Growth Factor (HGF)

a-1-Fucosidase

Annexin A2

Micro RNA

Circular RNAs

Cancer Stem Markers

CD44

CD133

CD90

Epithelial Cell Adhesion Molecule (EpCAM)

SURVEILLANCE AND HCC

TREATMENT STRATEGIES

Curative Treatments

Surgical Resection.

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.

Description based on print version record.

ISBN:

9789815039740

9815039741

OCLC:

1491309981